Journal: Cellular & molecular biology letters

Article Title: MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2.

doi: 10.1186/s11658-019-0188-3

Figure Lengend Snippet: Fig. 3 MiR-7-5p directly targets NOVA2 expression. a – The sequence of human miR-7-p and the predicted binding sites with miR-7-5p within the NOVA2 untranslated region (3′-UTR) are shown. b – MiR-7-5p treatment suppressed NOVA2 expression in A549 and SPCA-1 cells. The cells were cultured with or without miR-7-5p for 24 h, and then collected and used for western blotting assays to determine NOVA2 expression. β-actin was set as a loading control. The quantitative data from western blotting assays were measured with ImageJ software. Data are ratios of NOVA2 to β-actin. c – MiR-7-5p stimulation inhibited NOVA2 mRNA in A549 and SPCA-1 cells. A549 cells were co-transfected with luciferase plasmids containing the wild-type (WT) NOVA2 3′-UTR or mutant-type (Mut) NOVA2 3′-UTR. The cells were also treated with miR-7-5p at the same time. The cells were lysed to measure the relative luciferase activity. Quantitative data are presented as the means ± SEM, n = 3. ***p < 0.001 compared with the NC mimic group. d – NOVA2 expression in NSCLC tissues and adjacent non-tumor tissues was measured using qPCR. Quantitative data are presented as the means ± SEM. ***p < 0.001 compared with the NC mimic group. e – NOVA2 expression in a panel of human lung cell lines and human lung epithelial BEAS-2B cells. NOVA2 expression in BEAS-2B cells was set as 100%. Quantitative data are presented as the means ± SEM, n = 3. ***p < 0.001 compared with the BEAS- 2B group. f – Analysis of the correlation between miR-7-5p and NOVA2 expression in tumors. NOVA2 expression was inversely correlated with miR-7-5p expression in NSCLC tissues. The miR-206 mRNA level was set as the X axes, and the TFR1 mRNA level was set as the Y axes. R stands for goodness of fit. The p value stands for slope significance

Article Snippet: The NC and NOVA2 vectors were purchased from Origene.

Techniques: Expressing, Sequencing, Binding Assay, Cell Culture, Western Blot, Control, Software, Transfection, Luciferase, Mutagenesis, Activity Assay

Journal: Cellular & molecular biology letters

Article Title: MiR-7-5p suppresses tumor metastasis of non-small cell lung cancer by targeting NOVA2.

doi: 10.1186/s11658-019-0188-3

Figure Lengend Snippet: Fig. 4 NOVA2 overexpression reverses the inhibitory effect of miR-7-5p on A549 and SPCA-1 cells. a – NOVA2 overexpression partly decreased the miR-7-5p-mediated inhibitory effect on the proliferation of A549 and SPCA-1 cells. b and c – NOVA2 expression weakened the miR-7-5p-induced inhibitory effect on the migration of A549 and SPCA-1 cells. A549 and SPCA-1 cells were transfected with NOVA2 vector. After 24 h, the transfected cells were used for wound-healing assays. Representative images and quantitative data are shown in B and C, respectively. d and e – NOVA2 overexpression attenuated the miR-7-5p-mediated effect on the invasion of A549 and SPCA-1 cells. Representative images and quantitative data are shown in D and E, respectively. Quantitative data are presented as the means ± SEM. ***p < 0.001 compared with NC vector group. f – NOVA2 overexpression blocked miR-7-5p-mediated downregulation of EMT markers. A549 and SPCA-1 cells were transfected with NOVA2 vector or NC vector and then treated with miR-7-5p for 24 h. After that, the cells were collected and used for western blotting assays. The quantitative data from western blotting assays were measured with ImageJ software. Data are ratios of respective EMT marker to β-actin

Article Snippet: The NC and NOVA2 vectors were purchased from Origene.

Techniques: Over Expression, Expressing, Migration, Transfection, Plasmid Preparation, Western Blot, Software, Marker

Journal: Neurobiology of disease

Article Title: Identifying disulfidptosis-related biomarkers in epilepsy based on integrated bioinformatics and experimental analyses.

doi: 10.1016/j.nbd.2025.106789

Figure Lengend Snippet: Fig. 2. Identification of DE-DRMs in individuals with EP. (A) The heatmap of expression levels for nine DE-DRMs. (B) The expression levels of 11 DRMs were exhibited between Ctrl and EP groups in boxplots. (C) Correlation analysis of nine DE-DRMs. Red and green colors represent positive and negative correlations, respectively. (D) The PPI analysis of DE-DMRs showed that SLC3A2 interacted with SLC7A11, while NDUFS1 interacted with NDUFA11, NUBPL, and LRPPRC. Abbreviations: DE-DRMs, differentially expressed disulfidptosis-related molecules; EP, epilepsy; Ctrl, control; PPI, protein-protein interaction; SLC3A2, solute carrier family 3 member 2; SLC7A11, solute carrier family 7 member 11; NDUFS1, NADH:ubiquinone oxidoreductase core subunit S1; NDUFA11, NADH:ubiquinone oxidoreductase subunit A11; NUBPL, NUBP iron‑sulfur cluster assembly factor, mitochondrial; LRPPRC, leucine rich pentatricopeptide repeat containing. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Article Snippet: The paraffin sections were incubated with the primary antibodies (overnight, 4 ◦C): anti-GYS1 antibody (Sangon Biotech, D122431, dilution: 1:100), anti-NDUFS1 antibody (Abcam, ab185733, dilution: 1:100), anti-OXSM antibody (Boster, A12866–1, dilution: 1:100), anti-LRPPRC antibody (Abcam, ab259927, dilution: 1:200), anti-NDUFA11 antibody (Abclonal, A16239, dilution: 1:100) (Yang et al., 2022), anti-NUBPL antibody (Boster, A10634–1, dilution: 1:100), anti-NCKAP1 antibody (Bioworld Technology, BS71703, dilution: 1:50), anti-SLC3A2 antibody (Santa, sc-390,154, dilution: 1:50), anti-SLC7A11 antibody (Abcam, ab307601. dilution: 1:500).

Techniques: Expressing, Control

Journal: Neurobiology of disease

Article Title: Identifying disulfidptosis-related biomarkers in epilepsy based on integrated bioinformatics and experimental analyses.

doi: 10.1016/j.nbd.2025.106789

Figure Lengend Snippet: Fig. 8. The expression of DE-DRMs in seizures models (in vitro and in vivo). (A) Constructing the in vitro seizures model. The amplitude and frequency of neuronal APs in the Mg2+-free group were significantly increased (n = 6 in each group; Independent sample t-test; #, P < 0.01). (B) Protein expression of nine DE-DRMs in the in vitro seizures model. The expression of GYS1, NDUFS1, OXSM, LRPPRC, NDUFA11, NUBPL, NCKAP1, and SLC3A2 were not significantly changed in the Mg2+-free group, while the expression of SLC7A11 was significantly increased in Mg2+-free group (n = 6 in each group; Independent sample t-test; #, P < 0.01). (C) Con structing the in vivo seizures model. No epileptoid discharges were observed in six rats of the Ctrl group, while significant epileptoid discharges were observed in six rats of the PTZ group (scale: Y-axis,50uV; X-axis, 0.5 s). (D) Protein expression of nine DE-DRMs in vivo models. The expressions of GYS1, NDUFS1, OXSM, LRPPRC, NDUFA11, NUBPL, NCKAP1, and SLC3A2 were not significantly changed in PTZ group, while the expression of SLC7A11 was significantly increased in PTZ group (n = 6 in each group; Independent sample t-test; #, P < 0.01). Abbreviations: DE-DRMs, differentially expressed disulfidptosis-related molecules; APs, action potentials; GYS1, glycogen synthase 1; SLC3A2, solute carrier family 3 member 2; SLC7A11, solute carrier family 7 member 11; NDUFS1, NADH:ubiquinone oxidoreductase core subunit S1; OXSM, 3-oxoacyl-ACP synthase, mitochondrial; LRPPRC, leucine rich pentatricopeptide repeat containing; NDUFA11, NADH:ubiquinone oxidoreductase subunit A11; NUBPL, NUBP iron‑sulfur cluster assembly factor, mitochondrial; NCKAP1, NCK associated protein 1; PTZ, pentylenetetrazol.

Article Snippet: The paraffin sections were incubated with the primary antibodies (overnight, 4 ◦C): anti-GYS1 antibody (Sangon Biotech, D122431, dilution: 1:100), anti-NDUFS1 antibody (Abcam, ab185733, dilution: 1:100), anti-OXSM antibody (Boster, A12866–1, dilution: 1:100), anti-LRPPRC antibody (Abcam, ab259927, dilution: 1:200), anti-NDUFA11 antibody (Abclonal, A16239, dilution: 1:100) (Yang et al., 2022), anti-NUBPL antibody (Boster, A10634–1, dilution: 1:100), anti-NCKAP1 antibody (Bioworld Technology, BS71703, dilution: 1:50), anti-SLC3A2 antibody (Santa, sc-390,154, dilution: 1:50), anti-SLC7A11 antibody (Abcam, ab307601. dilution: 1:500).

Techniques: Expressing, In Vitro, In Vivo

Journal: Neurobiology of disease

Article Title: Identifying disulfidptosis-related biomarkers in epilepsy based on integrated bioinformatics and experimental analyses.

doi: 10.1016/j.nbd.2025.106789

Figure Lengend Snippet: Fig. 9. Verifying the PPI in seizures models (in vivo and in vitro). (A-B) colocation analysis indicated that SLC7A11 colocalized with SLC3A2, NDUFS1 colocalized with LRPPRC, NDUFS1 colocalized with NUBPL, and NDUFS1 colocalized with NDUFA11 in both primary neurons and hippocampal tissue. (C–D) Pooled quan tification of protein immunoprecipitation showed a significant increment in the pull-down of SLC7A11 and a significant reduction in the pull-down of NDUFA11 in both the Mg2+-free group and PTZ group (n = 6 in each group; Independent sample t-test; #, P < 0.01). Abbreviations: PPI, protein-protein interaction; SLC3A2,solute carrier family 3 member 2; SLC7A11, solute carrier family 7 member 11; NDUFS1, NADH:ubiquinone oxidoreductase core subunit S1; LRPPRC, leucine rich pentatricopeptide repeat containing; NUBPL, NUBP iron‑sulfur cluster assembly factor, mitochondrial; NDUFA11, NADH:ubiquinone oxidoreductase subunit A11; PTZ, pentylenetetrazol.

Article Snippet: The paraffin sections were incubated with the primary antibodies (overnight, 4 ◦C): anti-GYS1 antibody (Sangon Biotech, D122431, dilution: 1:100), anti-NDUFS1 antibody (Abcam, ab185733, dilution: 1:100), anti-OXSM antibody (Boster, A12866–1, dilution: 1:100), anti-LRPPRC antibody (Abcam, ab259927, dilution: 1:200), anti-NDUFA11 antibody (Abclonal, A16239, dilution: 1:100) (Yang et al., 2022), anti-NUBPL antibody (Boster, A10634–1, dilution: 1:100), anti-NCKAP1 antibody (Bioworld Technology, BS71703, dilution: 1:50), anti-SLC3A2 antibody (Santa, sc-390,154, dilution: 1:50), anti-SLC7A11 antibody (Abcam, ab307601. dilution: 1:500).

Techniques: In Vivo, In Vitro, Immunoprecipitation